Palonosetron: A novel 5-HT3 receptor antagonist for chemotherapy-associated nausea and vomiting

Formulary

Volumn 38, Issue 7, 2003, Pages 414-430

  DiVall, Margarita V ^a   Cersosimo, Robert J ^a  

^a NE University School of Pharmacy ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOLASETRON MESILATE; DOXORUBICIN; ONDANSETRON; PALONOSETRON; SEROTONIN 3 ANTAGONIST;

ABDOMINAL PAIN; BIOAVAILABILITY; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; ENTEROCHROMAFFIN CELL; HEADACHE; HUMAN; NAUSEA; NEUROTRANSMITTER RELEASE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; VASCULAR RESISTANCE; VERTIGO; VISUAL IMPAIRMENT;

EID: 0038506047     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Tortorice PV, O'Connell MB. Management of chemotherapy-induced nausea and vomiting. Pharmacotherapy 1990;10:129-145.
2. Gralla RJ, Osoba D, Kris MG. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999;17(9):2971-2994.
3. Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med 1993;329:1790-1796.
4. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-109.
5. 3 receptor antagonists or the prevention of chemotherapy-induced nausea and vomiting. Drugs 1998;55:173-189.
6. 3 receptor antagonist, in vivo. Br J Pharmacol 1995;114:860-866.
7. Palonosetron: Supportive care product candidate. Available at: http://www.mgipharma.com/. Accessed April 25, 2003.
8. 3 receptor in vitro. Br J Pharmacol 1995;114:851-859.
9. 3 receptor antagonist. J Med Chem 1993;36:2645-2657.
10. 3 receptor antagonist antiemetic for patients undergoing chemotherapy-based chemotherapy regimens? Blood 2001;98(11,Part 2):350b.
11. 3 receptor antagonist: palonosetron (RS-25259-197). Presented at: American Society of Clinical Oncology Meeting; May 12-15, 2001; San Francisco, Calif.
12. Pirracini G, Gallagher SC, Macchiocchi A. Palonosetron: a phase II dose ranging study to assess, over a 7-day period, the single-dose pharmacokinetic profile of palonosetron in patients receiving highly emetogenic chemotherapy. Presented at: American Society of Clinical Oncology Meeting; May 18-21, 2002; Orlando, Fla.
13. Anzemet (Dolasetron) [package insert]. Kansas City, Mo: Aventis Pharmaceuticals, Inc;2002.
14. Kytril (Granisetron) [package insert]. Nutely, NJ: Roche Pharmaceuticals; 2002.
15. Zofran (Ondansetron) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2001.
16. Macciocchi A, Chernoff SB, Hallagher SC, et al. A phase II dose-ranging study to assess single intravenous doses of palonosetron for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting. Presented at: American Society of Clinical Oncology Meeting; May 18-21, 2002; Orlando, Fla.
17. Fischer DS, Knobf MT, Durivage HJ, eds. The cancer chemotherapy handbook. St. Louis, Mo: Mosby-Year Book; 1993:499
18. Grunberg SM, Hajdenberg J, Charu V, et al. Palonosetron is active in preventing acute and delayed emesis following moderately emetogenic chemotherapy: Results of a phase III trial. Presented at: Multinational Association of Supportive Care in Cancer (MASCC) International Symposium; June 24-26, 2002; Boston, Mass.
19. Aapro MS, Selak E, Lichinitser M, et al. Palonosetron is more effective than ondansetron in preventing chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: results of a phase III trial. Presented at: American Society of Clinical Oncology Meeting; May 31-June 3, 2003; Chicago, Ill.
20. 3 receptor antagonist, demonstrates sustained prevention of nausea and vomiting for 5 dys following moderately emetogenic pharmacotherapy. Presented at: American Society of Clinical Oncology Meeting; May 31-June 3, 2003; Chicago, Ill.
21. 3 receptor antagonist. Presented at: American Society of Clinical Oncology Meeting; May 31-June 3, 2003; Chicago, Ill.
22. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer 2003;97(12):3090-3098.
23. 3 receptor antagonist: safety results of a phase III trial. Presented at: American Society of Clinical Oncology Meeting; May 31-June 3, 2003; Chicago, Ill.
24. Benedict CR, Arbogast R, Martin L, et al. Single blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol 1996;28:53-59.
25. Hunt TL, Cramer M, Shah A, et al. A double-blind, placebo controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers. J Clin Pharmacol 1995;35:705-712.
26. Hesketh P, Navari R, Grote T, et al, for the Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondanseton in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996;14:2242-2249.
27. Boike SC, Islon B, Zariffa N, et al. Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am J Health Syst Pharm 1997;54:1172-1176.
28. Ballard HS, Bottino G, Bottino J. Ondansetron and chest pain. Lancet 1992;340:1107.
29. Watanabe H, Hasegawa A, Shinozaki T, et al. Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue carcinomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol 1995;35:278-282.